---
title: "clinical_decision-making_and_treatment_of_myelodysplastic_syndromes"
slug: "clinicaldecision-makingandtreatmentofmyelodysplasticsyndromes"
date: "2024-05-12"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[treatment of myelodysplastic syndromes]]

# clinical_decision-making_and_treatment_of_myelodysplastic_syndromes

HellstrÃ¶m-Lindberg ES, KrÃ¶ger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023;142(26):2268-2281. doi:10.1182/blood.2023020079

Patient assessment and goal of treatment

- TD (transfusion dependency): 50% need RBC transfusion
-
- Initial decision-making
- Supportive care
- [[iron_chelation_therapy.md|Iron chelation therapy]]
- Criteria for response to treatment
- Growth factor treatment
- Luspatercept
- Immunosuppressive treatment
- Lenalidomide treatment
- Imetelstat and other novel targeted drugs for lower-risk MDS
- Hypomethylating agents
- HMA in combination with novel agents and molecularly targeted drugs
- Chemotherapy
- Stem cell transplantation
-

![Treatment algorithm for MDS](https://i.imgur.com/L68huoz.png)
